Member overview

Omeicos Therapeutics GmbH

  • founded as a spin-off from the Max-Delbrück-Center in Berlin
  • focus: designing and developing novel therapeutics (stable, synthetic analogs of highly bioactive natural metabolites of omega-3 fatty acids, called epoxyeicosanoids) that can be broadly deployed in inflammatory, cardiovascular, ophthalmology and other disease indications using its proprietary technology and extensive knowledge of omega-3 fatty acid metabolism and biology. 
  • The naturally occurring, but metabolically unstable epoxyeicosanoids have the ability to activate anti-inflammatory, anti-arrhythmic and cardioprotective pathways in cells, making them an attractive target for therapies directed towards a number of diseases including cardiovascular diseases, bronchial disorders, fatty liver disease and multiple eye disorders. 
  • The pipeline of small molecules are orally available and have shown significantly improved biological activity and pharmacokinetic properties compared to their natural counterparts.
  • Phase I clinical trial has been completed and revealed an excellent safety and tolerability profile for OMEICOS' lead candidate OMT-28. 


Please contact us for further information: